An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Who May Qualify: - Diagnosis of T1D for a minimum of 5 years - Stable diabetes regimen for at least 3 months prior to enrollment. Who Should NOT Join This Trial: - Medical history of islet cell, kidney, and/or pancreas transplant - Occurrence of 2 or more severe, unexplained hypoglycemic events within 6 months prior to enrollment - Known causes of diabetes other than T1D - Immunosuppressant therapy in the previous 30 days and/or requirements for chronic immunosuppressive therapy during the study - Prior treatment with gene therapy or edited product Always talk to your doctor about whether this trial is right for you.